Electra Therapeutics

ELA026 demonstrated a high overall response rate across a range of #sHLH patients. In patients with the poorest prognosis, those with malignancy-associated HLH, early treatment with ELA026 resulted in 100% ORR and improved survival.   Learn more about about positive results from our Phase 1b study in sHLH presented at #EHA2024

Excited that clinical data for our lead candidate ELA026 is selected as 1 of 6 abstracts for the late-breaking oral session at #EHA2024 on June 16 in Madrid & live-streamed. Data is from our ongoing Phase 1b study in patients with #sHLH, a life-threatening inflammatory disease.

We are delighted to have these exceptional leaders on our team: Graham Parry as CSO and Kim-Hien Dao as CMO. Their extensive experience and expertise in drug development will be invaluable at this time of great momentum for Electra.

We recently had the honor of hosting patient advocates Teresita Macias, Hernan Lara, and Dominque Boko who shared incredibly moving stories of their loved one’s journeys with #sHLH. Our team was inspired by their passion and dedication to raising awareness and finding a treatment. Together, we are committed to driving transformation change to those affected by this life-threatening inflammatory disorder.   Special thanks to Deanna Fournier, Director of the Histiocyte Organization, for connecting us with these inspiring voices. #raredisease

#RareDiseaseDay is a time to acknowledge the remarkable resilience of individuals around the world living with rare conditions, as well as their dedicated family members and friends. It also serves as a reminder to renew the global commitment to discovering new treatments that can address the unmet needs of these individuals. At Electra, we are actively contributing to this cause by advancing our lead clinical program, ELA026, in secondary Hemophagocytic Lymphohistiocytosis (sHLH) — a rare inflammatory condition that affects over 10,000 patients in the US annually. #rarediseaseday2024 #rarediseases

Don't miss this article in Fierce Biotech about our new CEO, Kathy Dong and the data we presented at #ASH23 this past weekend. 

Don't miss this article in Fierce Biotech about our new CEO, Kathy Dong and the data we presented at #ASH23 this past weekend. 

Excited to share our first clinical data at #ASH2023 for our lead candidate ELA026 in development for the treatment of #sHLH, a life-threatening inflammatory disease.  Data from ten sHLH patients in the ongoing Phase 1b clinical study showed favorable safety and overall response rate (ORR) of 70% in all patients dosed with ELA026. An ORR of 88% was observed in the eight patients with evaluable data. 

We are excited to announce the appointment of @Kathy Dong as President and CEO. This is an exciting time at Electra as the first clinical data for ELA026 was recently presented at #ASH2023, showing encouraging response rates in difficult-to-treat patients with sHLH, a life-threatening inflammatory disease.

Hope to see you at #ASH23 where we'll be presenting Phase 1b clinical data for our lead drug candidate ELA026 for secondary hemophagocytic lymphohistiocytosis (#sHLH), a life-threatening inflammatory disease. #Histiocytosis